Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

被引：172

作者：

Bodei, L

Cremonesi, M

Grana, C

Rocca, P

Bartolomei, M

Chinol, M

Paganelli, G

机构：

[1] European Inst Oncol, Div Nucl Med, I-20141 Milan, Italy

[2] European Inst Oncol, Med Phys Div, I-20141 Milan, Italy

来源：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2004年 / 31卷 / 07期

关键词：

Y-90-DOTATOC; neuroendocrine tumours; receptor radionuclide therapy; somatostatin receptors;

D O I：

10.1007/s00259-004-1571-4

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Somatostatin receptors are over-expressed in many tumours, mainly of neuroendocrine origin, thus enabling treatment with somatostatin analogues. Almost a decade of clinical experience of receptor radionuclide therapy with the analogue Y-90-[DOTA](0)-Tyr(3)-octreotide [Y-90-DOTATOC] has now been obtained at a few centres of excellence. This review reports on the present state of the art of receptor radionuclide therapy and discusses new perspectives.

引用

收藏

页码：1038 / 1046

页数：9

相关论文

共 43 条

[31] EXPERIMENTAL AND CLINICAL-STUDIES WITH SOMATOSTATIN ANALOG OCTREOTIDE IN SMALL-CELL LUNG-CANCER [J].

MACAULAY, VM ;

SMITH, IE ;

EVERARD, MJ ;

TEALE, JD ;

REUBI, JC ;

MILLAR, JL .

BRITISH JOURNAL OF CANCER, 1991, 64 (03) :451-456

[32] Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer [J].

Marschke, RF ;

Grill, JP ;

Sloan, JA ;

Wender, DB ;

Levitt, R ;

Mailliard, JA ;

Gerstner, JB ;

Ghosh, C ;

Morton, RF ;

Jett, JR .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (01) :15-17

[33]

*NAT COUNC RAD PRO, 1991, MIS RAD MAT MED SCI, P27

[34] Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer [J].

O'Byrne, KJ ;

Dobbs, N ;

Propper, DJ ;

Braybrooke, JP ;

Koukourakis, MI ;

Mitchell, K ;

Woodhull, J ;

Talbot, DC ;

Schally, AV ;

Harris, AL .

BRITISH JOURNAL OF CANCER, 1999, 79 (9-10) :1413-1418

[35] Yttrium-90 DOTATOC: first clinical results [J].

Otte, A ;

Herrmann, R ;

Heppeler, A ;

Behe, M ;

Jermann, E ;

Powell, P ;

Maecke, HR ;

Muller, J .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (11) :1439-1447

[36] Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide [J].

Paganelli, G ;

Zoboli, S ;

Cremonesi, M ;

Bodei, L ;

Ferrari, M ;

Grana, C ;

Bartolomei, M ;

Orsi, F ;

De Cicco, C ;

Mäacke, HR ;

Chinol, M ;

de Braud, F .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (04) :426-434

[37] MINI REVIEW - THE SOMATOSTATIN RECEPTOR FAMILY [J].

PATEL, YC ;

GREENWOOD, MT ;

PANETTA, R ;

DEMCHYSHYN, L ;

NIZNIK, H ;

SRIKANT, CB .

LIFE SCIENCES, 1995, 57 (13) :1249-1265

[38] Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use [J].

Reubi, JC ;

Schär, JC ;

Waser, B ;

Wenger, S ;

Heppeler, A ;

Schmitt, JS ;

Mäcke, HR .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (03) :273-282

[39] Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting [J].

Reubi, JC ;

Waser, B .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (05) :781-793

[40] Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands [J].

Reubi, JC ;

Waser, B ;

Schaer, JC ;

Laissue, JA .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (07) :836-846

← 1 2 3 4 5 →